FREMONT, Calif., Feb. 23 /PRNewswire-FirstCall/ -- WaferGen Biosystems,
Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art gene
expression, genotyping, cell biology and stem cell research systems, today
announced that the validation results of the company's SmartChip Real-Time PCR
System will be presented at Cambridge Healthcare Institute's 16th
International Molecular Medicine Tri-Conference. The data will be presented
by WaferGen scientists and collaborative researchers from the
Details of the poster presentation are as follows: Title: "High-Density, Nano-Volume SmartChip System for Real-Time Gene Expression Analysis" Time: From 9:40 a.m. (PST) on Wednesday, February 25 until 4:00 p.m. (PST) on Thursday, February 26 Summary: An overview of the company's novel whole genome, high-throughput SmartChip Real-Time PCR System, as well as data related to the system's performance as demonstrated in ongoing alpha testing
WaferGen's SmartChip alpha testing program, which is being conducted at
WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for gene expression, genotyping, cell biology and stem cell research for the life science and pharmaceutical industries. The company is actively developing its SmartChip(TM) product for the gene expression and genotyping markets. SmartChip is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform. This innovative system, combined with next-generation chemistry and optimized assays being developed by WaferGen, promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets. Based on collaborations established with leading research institutions, WaferGen believes that the SmartChip Real-Time PCR System is positioned as the platform of choice for biomarker discovery and validation. WaferGen currently markets its SmartSlide(TM) family of products to companies and organizations involved in stem cell and cell biology research. SmartSlide represents the first fluidics integrated micro-incubators enabling cell biology and stem cell research.
This press release contains certain "forward-looking statements". Such statements include statements relating to the company's goals, plans and projections, anticipated results of research, performance, reliability and cost-effectiveness of the company's SmartChip and other systems, and other statements that are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2007, and its subsequent Quarterly Reports on Form 10-Q filed with the SEC. Investors and security holders are urged to read this document free of charge on the SEC's web site at www.sec.gov. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Contact: Vida Communication (on behalf of WaferGen) Tim Brons (media) 415-675-7400 firstname.lastname@example.org
|SOURCE WaferGen Biosystems, Inc.|
Copyright©2009 PR Newswire.
All rights reserved